Fiche du document
3 septembre 2024
- handle: 10670/1.1rcyyb
- hal: hal-04707176
- doi: 10.1038/s41467-024-51453-z
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-024-51453-z
http://creativecommons.org/licenses/by/ , info:eu-repo/semantics/OpenAccess
Sujets proches
Communicable diseases--Vaccination Preventive inoculation Inoculation Preventive inoculation Diseases--VaccinationCiter ce document
Aurélie Wiedemann et al., « Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases », HALSHS : archive ouverte en Sciences de l’Homme et de la Société, ID : 10.1038/s41467-024-51453-z
Métriques
Partage / Export
Résumé
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of the immunology ancillary study of the trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, and rVSV–booster. Polyfunctional EBOV-specific CD4+ T-cell responses increase after Ad26 priming and are further boosted by MVA, whereas minimal responses are observed in the rVSV groups, declining after one year. In-vitro expansion for eight days show sustained EBOV-specific T-cell responses for up to 60 months post-prime vaccination with both Ad26-MVA and rVSV, with no decline. Cytokine production analysis identify shared biomarkers between the Ad26-MVA and rVSV groups. In secondary endpoint, we observed an elevation of pro-inflammatory cytokines at Day 7 in the rVSV group. Finally, we establish a correlation between EBOV-specific T-cell responses and anti-EBOV IgG responses. Our findings can guide booster vaccination recommendations and help identify populations likely to benefit from revaccination.